ORPHA:429
Hypochondroplasia
Publications
1,154
83.4th percentile
Trials
6
Interventional, condition-specific
Researchers
1,286
Distinct authors in sample
Gene link
FGFR3
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A primary bone with micromelia characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007793
- MeSH:C562937
- OMIM:146000
- UMLS:C0410529
- NCIT:C118697
Additional Mondo synonyms (1)
hypochondroplasia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — FGFR3
- LiteraturePresent
1,154 matched papers (503 in last 10 years) Source
- Phenotype characterisedPresent
39 HPO annotations (e.g. Widened interpedicular distance; Trident hand; Intellectual disability) Source
- Animal modelPresent
1 genotype model (Mus musculus) Source
- Orphan designationPartial
2 EMA designations (none yet with FDA orphan-indication approval) — e.g. Infigratinib Source
- Interventional trialPresent
6 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FGFR3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
39
Associated phenotypes · MONDO:0007793
- Widened interpedicular distance
- Trident hand
- Intellectual disability
- Craniosynostosis
- Malar flattening
Showing 5 of 39 — open Monarch for the full list.
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- Fgfr3tm3.1Llm/Fgfr3+ [background:] involves: C57BL/6N·MGI:7517089·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
2
Designations · no FDA orphan-indication approval yet
- EMA InfigratinibTreatment of hypochondroplasia · 21/11/2025 · PositiveEMA designation
- EMA vosoritideTreatment of hypochondroplasia · 13/12/2024 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0007793
- VOSORITIDE·phase 3
- SOMATROPIN·phase 2
- INFIGRATINIB·phase 2 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,154
1,154 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,154 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
503 in the last 10 years · medium confidence · 83.4th percentile (publications denominator)
Phrase hits: 1,154 · MeSH hits: 0
Who's working on it?
1,286
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Bober MB7 papers · 2025
Division of Orthogenetics, Nemours/ A.I. duPont Hospital for Children, Wilmington, DE, USA.
Papers in Europe PMC - 02Irving M7 papers · 2026
Department of Clinical Genetics Guy's and St Thomas NHS, London, UK.
Papers in Europe PMC - 03Dauber A6 papers · 2026
Division of Endocrinology, Children's National Hospital, Washington, DC 20010, USA.
Papers in Europe PMC - 04Cheung MS5 papers · 2026
Department of Paediatric Endocrinology, Great Ormond Street Hospital, London, UK.
Papers in Europe PMC - 05Fano V5 papers · 2025
Department of Growth and Development, Garrahan Hospital, Buenos Aires, Argentina.
Papers in Europe PMC - 06Legeai-Mallet L5 papers · 2026
INSERM U1163, Imagine Institute, Paris University , Paris,
Papers in Europe PMC - 07Merchant N5 papers · 2026
Division of Pediatric Endocrinology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Papers in Europe PMC - 08Savarirayan R5 papers · 2026
Victorian Clinical Genetics Services, Murdoch Children's Research Institute, University of Melbourne, Parkville, Victoria, Australia.
Papers in Europe PMC - 09Del Pino M4 papers · 2025
Department of Growth and Development, Garrahan Hospital, Buenos Aires, Argentina.
Papers in Europe PMC - 10Hoover-Fong J4 papers · 2026
McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; 4 currently recruiting in our sample.
Data as of 11 September 2026
6 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.1th percentile).
medium confidence · 90.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07393373·ENROLLING BY INVITATION·Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
- NCT06873035·ENROLLING BY INVITATION·An Interventional Study of Infigratinib in Children With Hypochondroplasia
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
- NCT07073014·ENROLLING BY INVITATION·Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
- NCT07126262·RECRUITING·A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07388966·RECRUITING·Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Not reviewed·Conditions: Achondroplasia · Hypochondroplasia·Matched via name phrase
- NCT05328050·RECRUITING·Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Not reviewed·Conditions: Achondroplasia · Hypochondroplasia·Matched via name phrase
- NCT06410976·RECRUITING·Prospective Clinical Assessment Study in Children With Hypochondroplasia
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
- NCT06212947·RECRUITING·A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Not reviewed·Conditions: Hypochondroplasia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (6)
- ctis·2025-523509-13-00·Authorised, ongoing·Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
skipped — LLM skipped (--skip-llm)
- ctis·2024-517238-16-00·Authorised, ongoing·A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia
skipped — LLM skipped (--skip-llm)
- ctis·2024-512261-14-00·Authorised, ongoing·A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months
skipped — LLM skipped (--skip-llm)
- ctis·2024-516822-67-00·Authorised, ongoing·A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3
skipped — LLM skipped (--skip-llm)
- ctis·2024-513129-22-00·Cancelled·A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11469487·No longer recruiting·Aromatase inhibitors in girls: Anastrozole combined to the LHRH analogue leuprorelin in Girls with early or precocious puberty and a compromised growth potential
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hypochondroplasia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hypochondroplasia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hypochondroplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T13:49:18.444Z
